Corcept Therapeutics Incorporated and Arrowhead Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis

Biotech Giants: Corcept vs. Arrowhead's Profit Journey

__timestampArrowhead Pharmaceuticals, Inc.Corcept Therapeutics Incorporated
Wednesday, January 1, 201417500025669000
Thursday, January 1, 201538200048925000
Friday, January 1, 201615833379263000
Sunday, January 1, 201731407709155647000
Monday, January 1, 201816142321246032000
Tuesday, January 1, 2019168795577300982000
Wednesday, January 1, 202087992066348292000
Friday, January 1, 2021138287000360697000
Saturday, January 1, 2022232810000396473000
Sunday, January 1, 2023240735000475894000
Monday, January 1, 20243551000
Loading chart...

Cracking the code

A Tale of Two Biotech Giants: Corcept vs. Arrowhead

In the dynamic world of biotechnology, Corcept Therapeutics Incorporated and Arrowhead Pharmaceuticals, Inc. have carved distinct paths over the past decade. From 2014 to 2023, Corcept's gross profit surged by an impressive 1,755%, reflecting its robust growth trajectory. In contrast, Arrowhead's gross profit, while more volatile, saw a remarkable increase of over 137,000% from its modest beginnings in 2014.

A Decade of Growth

Corcept consistently outperformed Arrowhead, with its gross profit peaking at nearly $476 million in 2023. Arrowhead, despite its fluctuations, reached a high of approximately $241 million in the same year. This disparity highlights Corcept's steady expansion and market strategy.

The Missing Year

Interestingly, 2024 data for Corcept is absent, leaving room for speculation on its future performance. As these companies continue to innovate, investors and industry watchers eagerly anticipate their next moves.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025